Tapping into evolving consumer preferences to deliver successful product launches helped Swisse cement its leadership position in 2023 as the number-one brand in China’s online dietary supplements market.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
More from Asia
• By
TikTok dietary supplement sales in Thailand grew by an astonishing 635% in 2024, while sales via Vietnam's and Malaysia's traditional e-commerce platforms increased by a still impressive 73% and 83% respectively.
• By
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.
• By
Organizations representing APAC health and medicines regulators and the consumer health industry respectively have agreed to “recognize the importance of self-care as a fundamental pillar of health and wellbeing” and “affirm our dedication to advancing self-care as an essential component of Universal Health Coverage.”
• By
Self-care industry representatives from GSCF/AESGP, Bayer and Opella stress the seriousness of the global climate crisis at the 2024 GSCF, APSMI, TSMIA Joint Congress in Bangkok, Thailand, and also share iniatives that are attempting to deal with this crisis, for example replacing PVC in medicine blister packs with more easily recyclable materials.
More from Geography
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.